[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.171.146.16. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 1,147
Citations 0
Correction
July 16, 2019

Clarification of Reporting of Potential Conflicts of Interest

JAMA. 2019;322(7):696. doi:10.1001/jama.2019.11017

In 3 Viewpoints published in JAMA,1-3 additional information was needed to clarify the conflict of interest disclosures. The Conflict of Interest Disclosures statements in 2 of the Viewpoints1,2 should have read as follows: “Dr Dzau reports having served previously as a member of the board of Medtronic Inc ending in June 2014 and receiving compensation from that company.” For the third Viewpoint,3 the disclosure statement should have read as follows: “Dr Dzau reports having served previously as a member of the board of Alnylam Pharmaceuticals ending in June 2014 and receiving compensation from that company.” These articles have been corrected online and a letter of explanation4 has also been published for further clarification.

References
1.
Dzau  VJ, Pizzo  PA.  Relieving pain in America: insights from an Institute of Medicine committee.  JAMA. 2014;312(15):1507-1508. doi:10.1001/jama.2014.12986PubMedGoogle ScholarCrossref
2.
Leshner  AI, Dzau  VJ.  Medication-based treatment to address opioid use disorder.  JAMA. 2019;321(21):2071-2072. doi:10.1001/jama.2019.5523PubMedGoogle ScholarCrossref
3.
Dzau  VJ, Ginsburg  GS.  Realizing the full potential of precision medicine in health and health care.  JAMA. 2016;316(16):1659-1660. doi:10.1001/jama.2016.14117PubMedGoogle ScholarCrossref
4.
Dzau  VJ.  Clarification of reporting of potential conflicts of interest in JAMA articles  [published online July 16, 2019].  JAMA. doi:10.1001/jama.2019.11051Google Scholar
×